AR133072A2 - Isolated antibodies or isolated antigen-binding fragments thereof that bind to the human leptin receptor (LEPR) and activate LEPR signaling - Google Patents
Isolated antibodies or isolated antigen-binding fragments thereof that bind to the human leptin receptor (LEPR) and activate LEPR signalingInfo
- Publication number
- AR133072A2 AR133072A2 ARP240101637A ARP240101637A AR133072A2 AR 133072 A2 AR133072 A2 AR 133072A2 AR P240101637 A ARP240101637 A AR P240101637A AR P240101637 A ARP240101637 A AR P240101637A AR 133072 A2 AR133072 A2 AR 133072A2
- Authority
- AR
- Argentina
- Prior art keywords
- lepr
- antibodies
- binding fragments
- antigen
- bind
- Prior art date
Links
Landscapes
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La presente invención proporciona anticuerpos y fragmentos de unión a antígeno de anticuerpos que se unen al receptor de leptina (LEPR), y métodos de uso de los mismos. De acuerdo con determinadas formas de realización, la invención incluye anticuerpos y fragmentos de unión a antígeno de anticuerpos que se unen a LEPR y activan la señalización de LEPR. En otras formas de realización, la invención incluye anticuerpos y fragmentos de unión a antígeno de anticuerpos que se unen a LEPR y mejoran la sensibilización de LEPR a un antígeno. En determinadas formas de realización, la invención incluye anticuerpos y fragmentos de unión a antígeno de anticuerpos que se unen a LEPR en presencia y en ausencia de leptina. En determinadas formas de realización, la invención incluye anticuerpos y fragmentos de unión a antígeno de anticuerpos que inducen la señalización en células que expresan mutantes de LEPR que, en otro caso, exhiben señalización defectuosa o dificultosa en presencia de leptina. Los anticuerpos y fragmentos de unión a antígeno de la presente invención son útiles para el tratamiento de lipodistrofias y otras enfermedades y trastornos asociados a la deficiencia de leptina o a la resistencia a la leptina o provocados por estas.The present invention provides antibodies and antigen-binding fragments of antibodies that bind to the leptin receptor (LEPR), and methods of using them. According to certain embodiments, the invention includes antibodies and antigen-binding fragments of antibodies that bind to LEPR and activate LEPR signaling. In other embodiments, the invention includes antibodies and antigen-binding fragments of antibodies that bind to LEPR and enhance sensitization of LEPR to an antigen. In certain embodiments, the invention includes antibodies and antigen-binding fragments of antibodies that bind to LEPR in the presence and absence of leptin. In certain embodiments, the invention includes antibodies and antigen-binding fragments of antibodies that induce signaling in cells expressing LEPR mutants that otherwise exhibit defective or impaired signaling in the presence of leptin. The antibodies and antigen-binding fragments of the present invention are useful for the treatment of lipodystrophies and other diseases and disorders associated with or caused by leptin deficiency or leptin resistance.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562240021P | 2015-10-12 | 2015-10-12 | |
| US202062359757P | 2020-07-08 | 2020-07-08 | |
| US202062375495P | 2020-08-16 | 2020-08-16 | |
| US202062393143P | 2020-09-12 | 2020-09-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR133072A2 true AR133072A2 (en) | 2025-08-20 |
Family
ID=96878002
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP240101637A AR133072A2 (en) | 2015-10-12 | 2024-06-26 | Isolated antibodies or isolated antigen-binding fragments thereof that bind to the human leptin receptor (LEPR) and activate LEPR signaling |
Country Status (1)
| Country | Link |
|---|---|
| AR (1) | AR133072A2 (en) |
-
2024
- 2024-06-26 AR ARP240101637A patent/AR133072A2/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2018003852A2 (en) | Antigen binding proteins that activate the leptin receptor | |
| UY40829A (en) | ANTI-PHF-TAU ANTIBODIES AND THEIR USES | |
| CL2020001575A1 (en) | Anti-trem2 antibodies and related methods. | |
| MX2024001803A (en) | ANTI-TREM2 ANTIBODIES AND METHODS OF USING THEM. | |
| CO2018011364A2 (en) | Anti-il-33 antibodies, compositions, methods and uses thereof | |
| MX374810B (en) | 4-1BB ANTI-HUMAN ANTIBODIES AND THEIR USES | |
| MX2016008472A (en) | ANTI-IL-33-HUMAN NEUTRALIZING MONOCLONAL ANTIQUER | |
| CO2018010458A2 (en) | Anti-tim-3 antibodies and compositions | |
| ECSP18096095A (en) | ALPHA-SINUCLEIN ANTIBODIES AND USES OF THEM | |
| CL2018000819A1 (en) | Bispecific anti-human cd20 antibodies / human transferrin receptor and methods for use | |
| MX2017012802A (en) | ANTISORTILINE ANTIBODIES AND METHODS FOR USE. | |
| CO2018001149A2 (en) | Monoclonal antibodies against bcma | |
| MX2017006323A (en) | ANTIBODIES UNDERSTANDING MODIFIED HEAVY CONSTANT REGIONS. | |
| CR20180318A (en) | BISPECIFIC MOLECULES THAT HAVE IMMUNORREACTIVITY WITH PD-1 AND CTLA-4, AND METHODS OF USE OF THE SAME | |
| BR112019005139A2 (en) | anti-il-33 antibodies and uses thereof | |
| CU24498B1 (en) | FACTOR XI ANTIBODIES | |
| AR103726A1 (en) | HUMAN ANTI-PD-1 MONOCLONAL ANTIBODY CRYSTALS | |
| MX2016006709A (en) | Aplnr modulators and uses thereof. | |
| CO2019007686A2 (en) | Monovalent anti-properdin antibodies and antibody fragments | |
| MX351127B (en) | Oncostatin m receptor antigen binding proteins. | |
| NI202000051A (en) | MONOCLONAL ANTIBODIES AND METHODS FOR USING THE SAME. | |
| CO2018010827A2 (en) | Anti-complement factor bb antibodies and uses of these | |
| CO2018012497A2 (en) | Interferon beta antibodies and uses thereof | |
| CL2025000292A1 (en) | TMEM219 antibodies and their therapeutic uses | |
| CR20190086A (en) | Antibody or an antigen-binding fragment thereof capable of binding to a human receptor of interleukin-6 |